BEGIN:VCALENDAR VERSION:2.0 PRODID:VideoCast CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT SUMMARY:Angelman Syndrome Treatment Opportunities and Clinical Biomarkers DTSTART:20200224T170000Z DTEND:20200224T180000Z DTSTAMP:20200224T141200Z UID:Videocast--35607 LOCATION:https://videocast.nih.gov/watch=35607 DESCRIPTION:Ben Philpot\, PhD\, UNC Chapel Hill School of Medicine\nNIH Neuroscience Series Seminar\n\nSeveral neurodevelopmental disorders are caused by mutations in different\, seemingly unrelated\, genes (e.g. – UBE3A and TCF4). However\, similar phenotypic manifestations suggest that these disorders share underlying cellular phenotypes\, or give rise to perturbances that converge pathophysiologically at the circuit level. Dr. Philpot lab employs an array of modern scientific approaches to understand the pathophysiology underlying monogenic neurodevelopmental disorders\, and leverage the knowledge gained from these approaches to develop gene therapies and novel drug treatments.\n\nDr. Philpot lab seeks to understand the pathophysiology underlying monogenic neurodevelopmental disorders\, and they use this information to develop therapeutics to treat these disorders. To accomplish these goals\, they employ a variety of techniques: electrophysiology\, biochemistry\, molecular biology\, optogenetics\, behavioral phenotyping\, gene therapy\, and small-molecule drug screening. They are particularly focused on developing transformative treatments for Dup15q syndrome\, Pitt-Hopkins syndrome\, and Angelman syndrome.\n\nFor more information go to 'https://neuroscience.nih.gov/neuroseries/home.aspz'>https://neuroscience.nih.gov/neuroseries/home.aspz X-ALT-DESC;FMTTYPE=text/html:\n\n
\n